RESEARCH ARTICLE

POST1/C12ORF49 regulates the SREBP pathway by promoting site-1 protease maturation

Jian Xiao, Yanni Xiong, Liu-Ting Yang, Ju-Qiong Wang, Zi-Mu Zhou, Le-Wei Dong, Xiong-Jie Shi, Xiaolu Zhao, Jie Luo, Bao-Liang Song

Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan 430072, China

Correspondence: jieluo@whu.edu.cn (J. Luo), blsong@whu.edu.cn (B.-L. Song)

Received April 12, 2020  Accepted June 17, 2020

ABSTRACT

Sterol-regulatory element binding proteins (SREBPs) are the key transcriptional regulators of lipid metabolism. The activation of SREBP requires translocation of the SREBP precursor from the endoplasmic reticulum to the Golgi, where it is sequentially cleaved by site-1 protease (S1P) and site-2 protease and releases a nuclear form to modulate gene expression. To search for new genes regulating cholesterol metabolism, we perform a genome-wide CRISPR/Cas9 knockout screen and find that partner of site-1 protease (POST1), encoded by C12ORF49, is critically involved in the SREBP signaling. Ablation of POST1 decreases the generation of nuclear SREBP and reduces the expression of SREBP target genes. POST1 binds S1P, which is synthesized as an inactive protease (form A) and becomes fully mature via a two-step autocatalytic process involving forms B'/B and C'/C. POST1 promotes the generation of the functional S1P-C'/C from S1P-B'/B (canonical cleavage) and, notably, from S1P-A directly (non-canonical cleavage) as well. This POST1-mediated S1P activation is also essential for the cleavages of other S1P substrates including ATF6, CREB3 family members and the α/β-subunit precursor of N-acetylglucosamine-1-phosphotransferase. Together, we demonstrate that POST1 is a cofactor controlling S1P maturation and plays important roles in lipid homeostasis, unfolded protein response, lipoprotein metabolism and lysosome biogenesis.

KEYWORDS SREBP, site-1 protease, proteolytic activation, unfolded protein response, activating transcription factor 6, mannose-6-phosphate

INTRODUCTION

Cholesterol metabolism is a complicated yet highly regulated process composed of biosynthesis, uptake, transport, utilization, export and esterification (Luo et al., 2020). Cholesterol biosynthesis and uptake represent the inputs and are switched on when cellular needs are unmet, whilst they are shut down when cellular needs are surpassed. Cholesterol within the cell is dynamically transported across the plasma membrane (PM) and various organelle membranes for serving as the membrane constituent, a signaling molecule and a precursor to other biologically active molecules (Luo et al., 2019). A balanced interplay of these pathways is essential for normal cellular functions and human health. Deregulation of cholesterol metabolism can lead to many disorders including cardiovascular disease, neurodegenerative disease and cancers (Ikonen, 2006; Kuzu et al., 2016; Chen et al., 2019).

One of the master regulators of cholesterol metabolism is sterol regulatory element-binding protein (SREBP) 2, which, through modulating expression of cholesterogenic enzymes and low-density lipoprotein (LDL) receptor (LDLR), governs cholesterol biosynthesis from acetyl-CoA and uptake from extracellular LDL particles. SREBP2 and the other two isoforms, SREBP1a and SREBP1c, are members of the
SREBP family belonging to basic helix-loop-helix-leucine zipper transcription factors (Horton et al., 2002). SREBP is initially synthesized as a precursor protein with the N- and C-terminal ends facing the cytosol and two transmembrane segments spanning the endoplasmic reticulum (ER). Upon cholesterol depletion, SREBP and the associated SREBP-cleavage activating protein (SCAP), with the help of Cideb, rapidly translocate from the ER to the Golgi apparatus (Su et al., 2019). At the Golgi, SREBP is cleaved by site-1 protease (S1P) in the lumenal loop followed by a second cleavage by site-2 protease (S2P) within the membrane-spanning domain (Brown and Goldstein, 1999). This liberates the N-terminal fragment that enters the nucleus and activates the transcription of genes controlling cholesterol biosynthesis and uptake, thereby restoring cellular cholesterol levels.

A corollary of the SREBP activation model is that factors involved in ER exit, ER-to-Golgi transport and Golgi tethering of the SREBP precursor, as well as those in generation of the nuclear form of SREBP (n-SREBP) can critically regulate SREBP signaling. For examples, under cholesterol repletion conditions, INSIGs, ERLINs and TRC8 are induced to bind and retain the SCAP/SREBP complex in the ER, thereby inactivating the SREBP pathway (Irisawa et al., 2009; Huber et al., 2013; Brown et al., 2018). By contrast, AKT and PAQR3 positively regulate the SREBP pathway by promoting anterograde trafficking and Golgi anchoring of the SCAP/SREBP complex, respectively (Du et al., 2006; Xu et al., 2015). Compared with the above mechanisms controlling localization of the SREBP precursor, how its cleavage at the Golgi is regulated is less clear.

S1P (also known as subtilisin kexin isozyme-1) is a serine protease of the subtilisin/kexin propionate convertase family (Seidah and Prat, 2012). The newly synthesized S1P is an inactive type I transmembrane precursor protein (pro-S1P) and requires multiple proteolytic events to become fully mature. Pro-S1P is first cleaved by a signal peptidase as it translocates into the ER lumen. This exposes the N-terminal prodomain that undergoes autocatalytic processing at RKVF$^{133}$ ↓ RSLK$^{137}$ ↓ RRAS$^{186}$ ↓ and RRLL$^{186}$ ↓ sequentially (Cheng et al., 1999; Espenshade et al., 1999; Elagoz et al., 2002; da Palma et al., 2014). The cleaved prodomain fragments remain associated with the rest of protein to assist correct folding while retaining enzymatic activity (da Palma et al., 2014; da Palma et al., 2016). Of all three S1P forms generated, only the completely processed protein can reach the Golgi where it acts on the SREBP precursor (Sakai et al., 1998; Espenshade et al., 1999). Despite the understanding of S1P autoprocessing, little is known whether and how, if any, this process is regulated.

In the present study, we use a genome-wide CRISPR/Cas9 knockout (KO) screen to search for new regulators involved in cholesterol homeostasis. An uncharacterized gene C12orf49 is found to be tightly correlated with the lower PM cholesterol level in our screen. We further demonstrate that C12orf49 interacts with S1P and affects cholesterol metabolism by promoting S1P maturation. Hence, we rename C12orf49 the partner of site-1 protease (POST1) to reflect its biological function. Depletion of POST1 reduces S1P-mediated proteolytic cleavage of SREBP2 and other S1P substrates. These results reveal POST1 as a newly identified factor of the SREBP pathway and S1P maturation.

**RESULTS**

**Genome-wide screen identifies that POST1 regulates cholesterol homeostasis**

We first set out to identify new regulators of cellular cholesterol homeostasis using a genome-scale CRISPR/
POST1 promotes S1P maturation

**A** HeLa/Cas9-Flag 
Lentivirus sgRNA libraries

HeLa/Cas9-Flag

Cholesterol depletion
LDL
SREBP-LDLR deficit
Trafficking deficit
AmB
Enriched

**B**

Log2(Fold change) vs. P value

- NPC1
- SCAP
- POST1
- LDLR

**C**

HeLa
HeLa/POST1 KO-1#
HeLa/POST1 KO-2#

**D**

Cytosol
Membrane
Lumen

**E**

POST1
Golgi
ER

**F**

| pCMV-POST1-EGFP | + |
|-----------------|---|
| Endo H          | - | + | - |
| PNGase F        | - | - | + |

POST1 (IB: EGFP)

ACTIN

© The Author(s) 2020
Cas9 knockout (GeCKO) screening strategy as depicted in Fig. 1A. Briefly, HeLa cells were transduced with lentivirus expressing the Streptococcus pyogenes Cas9 gene fused to a Flag tag to generate HeLa/Cas9-Flag stable cell line. The stable cells were then transduced with lentivirus expressing a pooled GeCKO v2 library containing 65,383 sgRNAs targeting 19,050 human genes at 0.3 multiplicity of infection (Sanjana et al., 2014). A four-day puromycin selection followed to allow the untransduced cells to be all killed. Surviving cells were deprived of cholesterol by incubating in the cholesterol-depletion medium containing lipoprotein-deficient serum plus lovastatin for 16 h. This condition activates the SREBP pathway so that LDLR expression is highly induced (Goldstein and Brown, 2009). Cells were then exposed to LDL and treated with amphotericin B (AmB), an antibiotic that binds cholesterol in the PM, forms pores and causes cell death (Wei et al., 2017).

We reasoned that the cells with normal SREBP activation and cholesterol trafficking machineries could upregulate LDLR expression, take up exogenous LDL and rapidly redistribute cholesterol towards the PM by several mechanisms (Chu et al., 2015; Infante and Radhakrishnan, 2017; Luo et al., 2017, 2019; Xiao et al., 2019), thereby failing the subsequent AmB selection due to PM leakage induced by AmB. By contrast, cells defective in either SREBP–LDLR axis or cholesterol trafficking had less PM cholesterol and were resistant to AmB treatment.

To ascertain that AmB selection was stringent enough to separate defective cells from the normal ones without inducing general cytotoxicity, we subjected untransduced HeLa/Cas9-Flag cells to a parallel “cholesterol depletion-repletion-AmB selection” challenge except that U18666A, which binds NPC1 and blocks lysosomal cholesterol export (Lu et al., 2015), was added together with LDL. Cells without AmB exposure and those treated with AmB alone were used as controls. Indeed, AmB-induced cell death was effectively rescued by U18666A (Fig. S1A).

After 5 rounds of challenges, the sgRNA inserts from surviving cells and those from transduced cells prior to the first round of challenge were amplified and subjected to deep sequencing. Candidate genes were identified using MAGeCK (Li et al., 2014). Those with at least 2 gRNA hits were selected and ranked by LFC (log2 fold change). The LFC cutoff value was set to >0.

A total of 115 genes were found highly enriched in the cells survived 5 rounds of challenge (Fig. 1B; Table S1), among which included NPC1, SCAP and LDLR, the well-established regulators of cholesterol trafficking and metabolism. Specifically, loss of NPC1 causes cholesterol accumulation in lysosomes whilst loss of SCAP impairs activation of the SREBP pathway. LDLR is a gatekeeper of LDL uptake as well as a target of SREBP2. Intriguingly, we also detected robust enrichment of an uncharacterized gene C12orf49, to which we referred as partner of site-1 protease (POST1) owing to its functional association with S1P (See below).

To confirm that POST1 is indeed a critical factor for cholesterol homeostasis, we generated two independent POST1 KO cell lines using the CRISPR/Cas9 technique followed by the cholesterol depletion-repletion-AmB selection challenge in the presence or absence of U18666A. Compared with wild-type (WT) cells that survived only when U18666A was added to AmB, POST1 KO cells showed markedly improved resistance to AmB even in the absence of U18666A (Fig. 1C). Overall, these results support a positive role of POST1 in regulating PM cholesterol level.

Human POST1 is a small protein of 205 amino acids. It is predicted to contain a cytosolic segment (1–16 aa), a transmembrane segment (17–36 aa), and a stretch of 169 amino acids extending into the lumen (Fig. 1D). To determine the subcellular location of POST1, HeLa cells were transfected with the plasmids encoding enhanced green fluorescent protein (EGFP)-tagged POST1 and DSRed-tagged KDEL (Lys-Asp-Glu-Leu), an ER retention motif, and then immunostained with the Golgi marker GM130. We detected robust POST1 staining colocalized with GM130 and modest signal colocalized with DsRed-KDEL (Fig. 1E). POST1 contains a potential N-linked glycosylation site (Fig. 1D). The transfected POST1 protein was partially sensitive to endoglycosidase H (Endo H), but completely shifted to a lower position by peptide N-glycosidase F (PNGase F) (Fig. 1F).

These results suggest that POST1 resides in both the ER and Golgi.
POST1 promotes S1P maturation

**RESEARCH ARTICLE**

A

| Protein | HeLa (FBS) | HeLa (Depletion) | HeLa (Depletion + 25-HC) | HeLa/POST1 KO (FBS) | HeLa/POST1 KO (Depletion) | HeLa/POST1 KO (Depletion + 25-HC) |
|---------|------------|-----------------|--------------------------|---------------------|---------------------------|----------------------------------|
| HMGCS1  |            | 0.5             | 0.6                       | 0.4                 | 0.5                       | 0.6                              |
| MSMO1   | 2.0        | 1.5             | 1.6                       | 2.2                 | 1.8                       | 1.9                              |
| SQLE    | 1.1        | 0.9             | 1.0                       | 1.3                 | 1.0                       | 1.2                              |
| MVD     | 0.8        | 0.7             | 0.8                       | 1.0                 | 0.9                       | 1.0                              |
| ID1     | 0.4        | 0.3             | 0.4                       | 0.5                 | 0.4                       | 0.5                              |
| HMGCR   | 1.2        | 1.1             | 1.2                       | 1.4                 | 1.3                       | 1.4                              |
| LDLR    | 0.6        | 0.5             | 0.6                       | 0.8                 | 0.7                       | 0.8                              |
| LSS     | 1.5        | 1.4             | 1.5                       | 1.7                 | 1.6                       | 1.7                              |
| DHCR7   | 0.9        | 0.8             | 0.9                       | 1.0                 | 0.9                       | 1.0                              |
| FADS1   | 1.3        | 1.2             | 1.3                       | 1.5                 | 1.4                       | 1.5                              |
| ACAT1   | 0.7        | 0.6             | 0.7                       | 0.8                 | 0.7                       | 0.8                              |
| PPARA   | 0.4        | 0.3             | 0.4                       | 0.5                 | 0.4                       | 0.5                              |
| SCD     | 0.9        | 0.8             | 0.9                       | 1.0                 | 0.9                       | 1.0                              |
| ACY1    | 1.1        | 1.0             | 1.1                       | 1.2                 | 1.1                       | 1.2                              |
| ELOVL6  | 1.4        | 1.3             | 1.4                       | 1.6                 | 1.5                       | 1.6                              |
| ACSL1   | 0.6        | 0.5             | 0.6                       | 0.7                 | 0.6                       | 0.7                              |
| INS1G1  | 0.4        | 0.3             | 0.4                       | 0.5                 | 0.4                       | 0.5                              |
| SLC22A6 | 0.8        | 0.7             | 0.8                       | 0.9                 | 0.8                       | 0.9                              |
| AC1      | 0.5        | 0.4             | 0.5                       | 0.6                 | 0.5                       | 0.6                              |
| FASNL   | 0.7        | 0.6             | 0.7                       | 0.8                 | 0.7                       | 0.8                              |
| LHBD1   | 0.9        | 0.8             | 0.9                       | 1.0                 | 0.9                       | 1.0                              |
| ALDOC   | 0.5        | 0.4             | 0.5                       | 0.6                 | 0.5                       | 0.6                              |
| NPR1    | 0.6        | 0.5             | 0.6                       | 0.7                 | 0.6                       | 0.7                              |
| BHLHE40 | 0.7        | 0.6             | 0.7                       | 0.8                 | 0.7                       | 0.8                              |
| SLC25A1 | 0.5        | 0.4             | 0.5                       | 0.6                 | 0.5                       | 0.6                              |
| CAV3    | 0.4        | 0.3             | 0.4                       | 0.5                 | 0.4                       | 0.5                              |
| PCYT2   | 0.6        | 0.5             | 0.6                       | 0.7                 | 0.6                       | 0.7                              |

Color key: 0, 1, 2, 3, 4

- Black: HeLa (FBS)
- Red: HeLa (Depletion)
- Blue: HeLa (Depletion + 25-HC)
- Orange: HeLa/POST1 KO (FBS)
- Red: HeLa/POST1 KO (Depletion)
- Blue: HeLa/POST1 KO (Depletion + 25-HC)

B

**Relative mRNA level (fold of HeLa cultured with FBS)**

C

| Protein | WT | HeLa/POST1 KO |
|---------|----|--------------|
| FBS     | +  | -            |
| Depletion | - | +            |
| Depletion + 25-HC | - | +            |

| kDa |
|-----|
| LDLR 100 |
| HMGCR 75  |
| SQLE 50  |
| CYP51A1 50 |
| FDFT1 37  |
| GAPDH 37  |
POST1 is engaged in the SREBP pathway

To gain insights into the mechanism by which POST1 governs cholesterol homeostasis, we treated WT and POST1 KO cells with three different conditions, namely (1) normal culture medium containing fetal bovine serum (FBS), or (2) cholesterol-depletion medium, or (3) cholesterol-depletion medium plus 25-hydroxycholesterol (25-HC), and then performed whole-transcriptome-sequencing (RNA-seq). The transcriptome data of WT cells exposed to FBS was used as a reference. In both WT and POST1 KO cells, the expression of SREBP2 target genes (cholesterol metabolism) and SREBP1c target genes (fatty acid metabolism) was markedly elevated upon cholesterol starvation (Fig. 2A; Table S2). However, these increases were much moderate when POST1 was ablated. 25-HC as a potent inhibitor of the SREBP pathway abrogated the upregulation of lipid metabolism-related genes caused by cholesterol depletion. The expression profiles of genes involved in cholesterol and fatty acid metabolism were further verified using quantitative real-time PCR and immunoblotting (Fig. 2B and 2C). In accordance with RNA-seq results, loss of POST1 impaired the responses of cholesterol biosynthetic genes (lanosterol synthase [LSS], HMGCR, 3-hydroxy-3-methylglutaryl-CoA synthase 1 [HMGCS1], squaene epoxidase [SQLE], cytochrome P450 family 51 subfamily A member 1 [CYP51A1], farnesyl-diphosphate farnesyltransferase 1 [FDFT1]) and fatty acid biosynthetic genes (stearoyl-CoA desaturase 1 [SCD1], fatty acid synthase [FASN], acetyl-coA carboxylase 1 [ACCT1]), as well as those of INSIG1 and LDLR to cholesterol depletion (Fig. 2B). SCAP and INSIG2 are not SREBP target genes and their expression remained unaltered regardless of treatments (Fig. 2B). At the protein level, the amounts of LDLR and representative cholesterol biosynthetic enzymes were similarly increased by cholesterol depletion and decreased by 25-HC, and in a lesser extent in POST1 KO cells (Fig. 2C).

To investigate whether POST1 is directly involved in SREBP processing, we prepared a plasmid that encodes full-length SREBP2 with a Flag epitope tag at the N terminus (Flag-SREBP2). This allows tracing of SREBP2 under both cholesterol-rich and cholesterol-depleted conditions, the latter of which induces SREBP2 to liberate the N-terminal fragment (n-SREBP2) that translocates into the nucleus. WT and POST1 KO cells were transfected with Flag-SREBP2 and challenged with varying levels of cholesterol, and the subcellular localization of SREBP2 was examined using the anti-Flag antibody. WT cells cultured in 10% FBS showed an ER distribution of SREBP2 (Fig. 3A, top row; Fig. 3C and 3D), whereas those deprived of cholesterol had robust staining in the nucleus (Fig. 3A, middle row; Fig. 3C). 25-HC blocks the ER-to-Golgi transport of SREBPs (Radhakrishnan et al., 2007), and SREBP2 was mainly found in the ER of WT cells exposed to 25-HC (Fig. 3A, bottom row). With respect to POST1 KO cells, SREBP2 was predominately localized in the ER in the presence of ample cholesterol (Fig. 3B, top row), but redistributed to the Golgi complex with slight staining in the nucleus upon cholesterol depletion (Fig. 3B, middle row; Fig. 3C and 3D). Interestingly, 25-HC decreased both Golgi and nuclear SREBP2 staining to the levels seen in FBS-treated cells (Fig. 3B, bottom row; Fig. 3C and 3D). In line with these immunostaining results, n-SREBP2 was evident in WT cells depleted of cholesterol but barely detectible in POST1 KO cells (Fig. 3E). We generated three independent lines of POST1 KO cells and found markedly reduced n-SREBP2 compared with WT controls (Fig. 3F and S1B). Further, knockdown of POST1 using small interfering RNA (siRNA) hampered cholesterol depletion-induced SREBP2 cleavage to a similar extent as knockdown of SCAP (Fig. 3G and S1C). Together, these results establish POST1 as a key regulator of SREBP processing.

POST1 promotes autocatalytic cleavage of S1P

We next sought to investigate the molecular mechanism by which POST1 regulates the SREBP pathway. HeLa cells stably expressing POST1-Flag were generated and the potential binding proteins of POST1 were identified using co-immunoprecipitation coupled to tandem mass spectrometry.
POST1 promotes S1P maturation

Protein & Cell

© The Author(s) 2020
S1P is synthesized as an inactive precursor whose domain organization is shown in Fig. 4C. To become mature, S1P undergoes multiple processing of the N-terminal prodomain involving the catalytic triad D218/H249/S414, generating three shortened forms designated S1P-A, S1P-B/B and S1P-C/C (Espenshade et al., 1999; Elagoz et al., 2002; da Palma et al., 2014). Indeed, immunoblotting analysis of HeLa cells transfected with a plasmid encoding S1P fused with a C-terminal Flag tag (S1P-Flag) showed three bands corresponding to differently cleaved forms of S1P (Fig. 4D).

Co-expression of POST1 increased S1P-C/C production and eliminated S1P-B/B (Fig. 4D). We next evaluated the impact of POST1 on processing of transfected S1P in the cells lacking the endogenous counterpart (Fig. S1D). As in the WT cells, POST1 promoted S1P-C/C generation at the expense of S1P-B/B as well (Fig. 4E, compare lanes 1 and 2). No S1P autoprocessing was detected when enzymatically inactive mutant (EM, D218A/H249A/S414A) was expressed alone (lane 3) or together with POST1 (lane 4), suggesting that S1P enzymatic activity is a prerequisite for its self-cleavage regardless of the presence of POST1. The B/B cleavage site mutant (BM, R130E/R134E) of S1P failed to yield S1P-B/B and S1P-C/C (lane 5), whereas the C/C mutant (CM, R163E/R164E/R183E/R184E) could generate S1P-B/B but failed to yield S1P-C/C (lane 7). These results are consistent with the earlier work (Espenshade et al., 1999; da Palma et al., 2014), and suggest that S1P cleavage at the B/B sites is required for subsequent cleavage at the C/C sites. However, we observed S1P-C/C, albeit in small amounts, in S1P-KO cells co-transfected with S1P B/B mutant and POST1 (lane 6), suggesting that POST1 may aid S1P autoprocessing bypassing the B/B sites. By contrast, POST1 had no effect on the autoprocessing of S1P with C/C mutations (lane 8).

It should be noted that S1P used in the above experiments had a Flag tag at the C terminus, which provided limited information on the self-cleavage steps occurring within the N-terminal prodomain. Therefore, to examine whether POST1 facilitates generation of S1P-C/C directly from S1P-A, we prepared plasmids that encode two HA-tagged versions of S1P-Flag, designated HA-1 and HA-2. The HA epitope tag was inserted in the prodomain between A and B/B sites (prodomain I) in HA-1, and between B/B and C/C sites (prodomain II) in HA-2 (Fig. 4F). S1P-Flag, HA-1 or HA-2 was transfected into HeLa cells alone or in combination with POST1, and S1P autoprocessing was analyzed by immunoblotting. The anti-Flag blot (Fig. 4F, the 1st blot) showed that POST1 increased S1P-C/C formation when co-expressed with S1P-Flag, HA-1 or HA-2. However, in the anti-HA blot, we detected S1P-A and a 14-kDa band corresponding in size to the prodomain I in the cells transfected with the HA-1 plasmid, but A and B/B forms in the cells transfected with the HA-2 plasmid (lanes 3 and 5 of the 2nd and 3rd blots). These results are in accordance with the canonical cleavage event in which S1P-A is converted to S1P-B/B and then to S1P-C/C. Theoretically, the prodomain II generated from HA-2 should also be visible, and we attribute its absence to the small protein size (~5 kDa). Upon POST1 co-expression, a band corresponding to the prodomain (I+II) appeared in the cells expressing HA-1 or HA-2 (lanes 4 and 6 of the 3rd blot). These results support the notion that POST1 promotes S1P-A cleavage at the C/C sites. In addition, S1P-B/B was dramatically decreased when POST1 was co-expressed (compare lanes 5 and 6 of the 2nd blot), indicating POST1 also promotes S1P-B/B cleavage at the C/C sites. Together, we propose that POST1 accelerates generation of mature S1P-C/C from S1P-B/B via a canonical cleavage as well as from S1P-A directly via a non-canonical cleavage (Fig. 6I).

We next investigated the effect of POST1 on S1P subcellular location using HeLa cells transfected with S1P-Flag alone or in combination with POST1-EGFP. In the absence of POST1, the majority of S1P resided in the ER and only about 12% of S1P was found colocalized with GM130 (Fig. 5A and 5B). Co-expression of POST1 caused a greater than 5-fold increase in S1P localization to the Golgi complex (Fig. 5A and 5B). Notably, mutations in enzymatic activity (EM) and B/B or C/C cleavage sites (BM and CM) severely impaired POST1-induced translocation of S1P from the ER to the Golgi (Fig. 5C and 5D). As these mutants (EM, BM and CM) produced little or no S1P-C/C (Fig. 4E), it is concluded that POST1 facilitates the generation of S1P-C/C.
POST1 promotes S1P maturation

Proteins interacted with POST1

Top 15:
- S1P
- OS9
- SLC39A7
- EIF2B4
- ECEL1
- YTHDF2
- ACTL8
- MRPL4
- CLPX
- RBM47
- ERLEC1
- SEL1L
- XPOT
- TGFBR1
- IPO9

Enzymatic sites

S1P Mut: BM (R130E/R134E) CM (R163E/R164E/R83E/R184E) EM (D218A/H249A/S414A)

© The Author(s) 2020

Protein & Cell

RESEARCH ARTICLE
that is subsequently transported to the Golgi. Co-expression of S1P and POST1 dramatically promoted the nuclear localization of SREBP2 (Fig. S2A; Movie S1).

To address where POST1-stimulated S1P processing occurs, we prepared plasmids encoding POST1 with a C-terminal EGFP followed by a KDEL or KDAS (Lys-Asp-Ala-Ser) tetrapeptide sequence. The KDEL tail is supposed to confer constitutive ER localization of POST1-EGFP, whereas the KDAS tail should be non-functional and serves as a negative control. To validate the localization of POST1-EGFP, POST1-EGFP-KDEL and POST1-EGFP-KDAS, lysates from cells transfected with various plasmids were treated with Endo H or PNGase F. As expected, only POST1-EGFP-KDEL was completely sensitive to Endo H, and the other two proteins were partially resistant to Endo H (Fig. 5E). These results indicate that POST1 promotes self-cleavage of S1P in the ER and that the generated S1P-C/C still binds to POST1.

Figure 5. POST1 facilitates translocation of mature S1P to the Golgi. (A) HeLa cells were transfected with either pCMV-S1P-3×Flag (red) alone or in combination with pEGFP-N1-POST1 (green) for 48 h. Cell were fixed and immunostained with the antibodies against Flag and GM130 (white). Nuclei were counterstained with DAPI (blue). Scale bar, 10 μm. (B) Percentages of S1P intensity in the Golgi normalized to the total S1P intensity in (A). Data are presented as mean ± SD (10 cells/trial; 3 independent trials). Unpaired two-tailed Student’s t-test. ***P < 0.001. (C) HeLa cells were co-transfected with pCMV-POST1-EGFP (green) and pCMV-S1P-3×Flag variants (red) for 48 h. Cell were fixed and immunostained with the antibodies against Flag and GM130 (white). BM, B/B cleavage site mutations; CM, C/C cleavage site mutations; EM, enzymatic site mutations. The S1P variants were illustrated in Fig. 4C. Scale bar, 10 μm. (D) Percentages of S1P intensity in the Golgi normalized to the total S1P intensity in (C). Data are presented as mean ± SD (10 cells/trial; 3 independent trials). One-way ANOVA with Tukey HSD post hoc test. ***P < 0.001. (E) HeLa cells were transfected as indicated for 48 h and subjected to immunoblotting. (F) HeLa cells were co-transfected with pCMV-S1P-3×Flag (red) and different variants of pCMV-POST1-EGFP (green) for 48 h. Cells were fixed and immunostained with the antibodies against Flag and GM130 (white). Scale bar, 10 μm. (G) Percentages of S1P intensity in the Golgi normalized to total S1P intensity in (F). Data are presented as mean ± SD (10 cells/trial; 3 independent trials). One-way ANOVA with Tukey HSD post hoc test. ***P < 0.001, ns, no significance.
POST1 promotes S1P maturation

RESEARCH ARTICLE

© The Author(s) 2020
Figure 6. POST1 affects proteolysis of other S1P substrates. (A) HeLa and HeLa/POST1 KO cells were treated with 2 μmol/L thapsigargin (Tg) for the indicated periods, and the processing of endogenous ATF6 was analyzed by immunoblotting. Pre, precursor; n, nuclear. (B) HeLa and HeLa/POST1 KO cells were transfected with pCMV-5xMyc-CREB3L3 for 48 h and treated with 2 μmol/L thapsigargin for the indicated periods. The processing of transfected CREB3L3 was analyzed by immunoblotting. Pre, precursor; n, nuclear. (C) HeLa and HeLa/POST1 KO cells were transfected with pCMV-GNPTAB mini-construct for 48 h, and the processing of transfected α/β-subunit precursor was analyzed by immunoblotting. (D) Immunoblot analysis of HeLa, HeLa/1P KO and HeLa/POST1 KO cells using the anti-M6P antibody and GAPDH antibody. (E) Activity of α-mannosidase in the whole cell lysates and medium of HeLa and HeLa/POST1 KO cells. Values in HeLa cells were set to 1. Data are presented as mean ± SD (2 samples/trial; 3 independent trials). Unpaired two-tailed Student’s t-test, *P < 0.05, ***P < 0.001. (F) HeLa cells were transfected with the indicated siRNAs for 48 h, and stained with Lysotracker (red) for 30 min. Cells were then fixed and immunostained with the antibodies against LAMP1 (green). Scale bar, 10 μm. (G) HeLa cells were transfected with the indicated siRNAs for 48 h, fixed, stained with filipin (blue) and immunostained with the antibody against lysy-bis-phosphatidic acid (LBPA, green). Scale bar, 10 μm. (H) Quantification of filipin, Lysotracker and LBPA intensity in HeLa and HeLa/POST1 KO cells shown in (F) and (G). Data are presented as mean ± SD (10 cells/trial; 3 independent trials). Unpaired two-tailed Student’s t-test. ***P < 0.001. (I) Schematic representation of POST1-promoted S1P maturation. POST1 accelerates the canonical autocleavage of S1P-B/B at the C/C sites, and the non-canonical autocleavage of S1P-A directly at the C’/C’ sites.

POST1 largely inhibited the cleavage of the α/β-subunit precursor to release α and β subunits. In line with this, the overall levels of M6P-modified proteins were reduced in cells lacking POST1 or S1P (Fig. 6D). The intracellular abundance of α-mannosidase, an M6P-modified lysosomal enzyme, was significantly decreased but its secretion to the medium was greatly increased (Fig. 6E). We next examined the volume of lysosomes using the LAMP1 antibody and Lysotracker. Lysosome enlargement is a sign of dysfunction (te Vruchte et al., 2014; Xu et al., 2014). POST1-deficient cells had enlarged lysosomes as revealed by the LAMP1 and lysotracker staining (Fig. 6F). Defective lysosomal homeostasis in the absence of POST1 eventually caused massive accumulation of cholesterol and lysy-bis-phosphatidic acid (LBPA) in the cell (Fig. 6G and 6H), since lysosomal proteins such as NPC2 need M6P modification for lysosomal targeting (Wei et al., 2017).

DISCUSSION

The impetus of the present study was to identify uncharacterized factors that regulate cholesterol metabolism. For this purpose, we performed a genome-scale, unbiased CRISPR/Cas9 KO screen coupled to the “cholesterol depletion-repletion-AmB selection” challenge (Fig. 1A), so that genes involved in LDL uptake and cholesterol trafficking to the PM were highly enriched. Our screen uncovered C12orf49/POST1, the loss of which increased AmB resistance (Fig. 1C), attenuated SREBP target gene expression (Fig. 2A and 2B) and blocked SREBP processing (Fig. 3). Further examination showed that POST1 modulated SREBP signaling by accelerating generation (Fig. 4) and Golgi localization (Fig. 5) of mature S1P. In addition to SREBP activation, POST1-mediated S1P maturation is also critical for the cleavage of other S1P substrates including ATF6, CREB3L3 and the α/β-subunit precursor of GlcNAc-1-phosphotransferase (Fig. 6). These results set POST1 as a key determinant for S1P maturation and lipid metabolism. Based on these findings, we attribute the survival of POST1-deficient cells in the AmB screen to two reasons: 1) low LDLR expression as a result of impaired cleavage of SREBP2 (Figs. 2C and 3E); and 2) defective lysosomal cholesterol transport as a result of impaired cleavage of the α/β-subunit precursor of GlcNAc-1-phosphotransferase (Fig. 6C and 6G).

All nine members of the mammalian proprotein convertase family are synthesized as a zymogen and activated by autocatalytic cleavages of the N-terminal prodomain (Seidah and Prat, 2012). However, the self-processing of S1P is particularly complicated involving four identified cleavage sites (‘B’, ‘B’, C’ and C) and multiple cleavage steps, first at the B/B sites and then at the C/C sites, yielding various forms of S1P with prodomain segments of different lengths bound non-covalently (Espinashade et al., 1999; Elagöz et al., 2002; da Palma et al., 2014). Contrasting to those in other proprotein convertases that function as an inhibitor, the
prodomain of S1P is crucial for its folding, autoprocessing and proteolysis of substrates including SREBP2 (da Palma et al., 2014; da Palma et al., 2016). Another unique aspect of S1P is that it needs not to be completely processed to become enzymatically active, as S1P-B'/B resides in the ER and so does SREBP under cholesterol repletion conditions, in which the SREBP pathway is known to shut down. Instead, the B'/B forms may function both as the catalyst and substrate to give rise to the fully mature enzyme that can reach the Golgi and selectively deal with the translocated SREBP as a result of cholesterol depletion. Here, we demonstrate that POST1 is a S1P cofactor that promotes generation of S1P-C/C, either from S1P-B'/B (canonical cleavage) or directly from S1P-A (non-canonical cleavage).

It is reported that all the S1P precursors reside in the ER and the mature S1P-C/C resides in the Golgi (DeBose-Boyd et al., 1999). We demonstrate that POST1-EGFP-KDEL facilitates the production of S1P-C/C, and that the S1P mutants that cannot be converted to the active form are mainly present in the ER (Fig. 5C and 5G). These data suggest that POST1 facilitates S1P-C/C production in the ER and then they are transported to Golgi together. The mechanism by which POST1 contributes to S1P-C/C production is unknown. However, this process is abolished by the D218A/H249A/S414A mutations (Fig. 4E), suggesting an absolute dependency on S1P enzymatic activity. Since autoprocessing at the C/C sites is reported to occur in trans involving another S1P protein (Espenshade et al., 1999; da Palma et al., 2014), we speculate that POST1 may facilitate this intermolecular reaction by bringing two immature S1Ps in an optimal distance or orientation, so that one as the substrate can access the catalytic triad of another. It will also be interesting to examine whether POST1 affects autoprocessing of proprotein convertase subtilisin kexin 9 (PCSK9), which is classified as non-basic proprotein convertases along with S1P and, importantly, serves as an emerging drug target for hyperlipidemia and cardiovascular disease (Burke et al., 2017). The physiological regulator of POST1 is worth investigating as well.

During the preparation of our manuscript, C12ORF49 was identified as a key determinant of the SREBP pathway (Aregger et al., 2020; Bayraktar et al., 2020; Loregger et al., 2020). They all found that absence of C12ORF49 reduced expression of SREBP target genes or impaired SREBP cleavage, which are consistent with our results. All their results can be explained by our finding that POST1 is required for S1P maturation. For example, Loregger et al. found that knockout of C12ORF49 decreased SCAP protein level and caused SCAP relocation to the Golgi regardless of sterol levels. We believe that these phenotypes should be attributable to impairments in C12ORF49-mediated S1P maturation, and defective SREBP cleavage by S1P then prevents Golgi-to-ER transport of SCAP and causes SCAP degradation in lysosomes (Shao and Espenshade, 2014). Consistently, depletion of POST1 or S1P similarly reduced SCAP level (Fig. S3A and S3B). As cholesterol depletion promotes ER-to-Golgi transport of SCAP and SCAP is degraded when SREBP cannot be efficiently cut by S1P, less SCAP was detected in POST1-KO cells under the sterol-depletion condition (Fig. S3A). If the reduced SCAP was the cause of impaired SREBP cleavage, the SREBP cleavage should be rescued by brefeldin A, an ER-Golgi protein trafficking inhibitor that disassembles and redistributes the Golgi complex into the ER (Schiwy et al., 1997). However, BFA largely restored the SREBP2 cleavage in the SCAP knockdown cells, with no effect on POST1 knockdown cells (Fig. S3C). So, less SCAP in POST1 KO cells is not the direct cause of impaired SREBP cleavage.

In summary, our study shows that POST1 is a cofactor of S1P. It promotes autocatalytic cleavage of S1P at the C/C sites from immature S1P-A and S1P-B'/B. Through modulating S1P maturation, POST1 is critically involved in the processing of SREBP, ATF6, CREB3 family members and other S1P substrates.

METHODS

Reagents

Mevalonolactone (No. M4667), filipin (No. F9765), oleic acid (No. O1008), 25-HC (No. H1015) and anti-Flag M2 Affinity Gel (No. A2220) were from Sigma Aldrich. LysoTracker Red DND-99 (No. L7528) and DAPI (No. D3571) were from Invitrogen. Blisticidin (No. 60218ES10) was from Yeasen. Endoglycosidase H (No. P0703S) and peptid Tag N-glycosidase F (No. P0704S) were from New England Biolabs. Liporprotein-deficient serum (LPDS, density >1.215 g/mL) was prepared from newborn calf serum by ultracentrifugation in our laboratory.

Primary antibodies

The following antibodies were used in this study: mouse anti-ATF6 (Protein Tech No. 66563-1-lg), rabbit anti-a-subunit of GNPTAB (Abclonal Technology No. A15895), mouse anti-b-actin (Sigma No. A1978), mouse anti-clathrin heavy chain (BD Transduction Laboratories No. 610499), rabbit anti-CYP51A1 (ProteinTech No. 13431-1-AP), rabbit anti-EGFP (ProteinTech No. 50430-2-AP), mouse anti-FDFT1 (Santa Cruz Biotechnology No. sc-271602), mouse anti-Flag tag (ProteinTech No. 66008-3-lg), mouse anti-GAPDH (ProteinTech No. 60004-1-lg), mouse anti-GM130 (BD Transduction Laboratories No. 610823), mouse anti-lamin B1 (ProteinTech No. 66095-1-lg), mouse anti-lyso-bis-phosphatidic acid (LBPA) (Echelon Biosciences No. Z-PLPRA), rabbit anti-Myc tag (ProteinTech No. 16286-1-AP), mouse anti-squalene epoxidase (Santa Cruz Biotechnology No. sc-271651). The polyclonal antibody against LDLR, the monoclonal antibody against HMGCR (A9), and the monoclonal antibody against SREBP2 (1D2) were prepared in our laboratory. The scFv (single-chain Fragment variable) M6P (mannose 6-phosphate) antibody was a kind gift from Dr. Thomas Braulke (University Medical Center
POST1 promotes S1P maturation

Hamburg-Eppendorf, Germany). Primary antibodies were used at the dilution of 1:500 for immunofluorescent staining and 1:1,000 for immunoblotting.

Plasmids

The coding sequences of MBTPS1 (S1P) and POST1 (C12orf49) were amplified from HeLa cells by standard PCR and inserted into pEGFP-N1, p3xFlag-CMV14 or pcDNA3.0 vectors to generate pCMV-POST1-EGFP, pCMV-S1P/POST1-3xFlag and pCMV-S1P/POST1, respectively. The sequence of POST1-3xFlag was sub-cloned from pCMV-POST1-3xFlag by standard PCR, and then inserted into the pLVX-iRES-Puro vector for lentivirus preparation. The sequence of 5’Myc tag was inserted into the C terminus of pCMV-S1P and pCMV-POST1 using site-directed mutagenesis via PCR. The sequences of KDAS and KDEL were inserted into the C terminus of pCMV-POST1-EGFP by overlap extension PCR. The mutant forms of S1P-EM (D218A/H249A/S414A), BM (R130E/R134E), CM (R163E/R164E/R183E/R184E) were prepared by site-directed mutagenesis. For pCMV-HA-1/HA-2-S1P-3xFlag, the sequence of HA tag (YPYDVPDYA) was inserted immediately after the sequence encoding the 30th and 152th amino acid of S1P protein in pCMV-S1P-3xFlag by site-directed mutagenesis. The coding sequence of Creb3/3 (Addgene No. 99509) was sub-cloned into pcDNA3.0, and the sequence of 5’Myc tag was inserted into the N terminus Creb3/3 to generate pCMV-5’Myc-Creb3/3, pCMV-GNPTAB (No. 78107), LentiCas9-Flag plasmid (No. 100000049) and human CRISPR/Cas9 knockout pooled library (GeCKO v2) (No. 1000000048) were from Addgene.

Cell culture

HeLa cells stably expressing POST-3xFlag (HeLa/POST-3xFlag) or stably expressing Cas9 (HeLa/Cas9-Flag) were generated by transducing HeLa cells with lentivirus expressing POST1-3xFlag or Cas9-Flag for 24 h. Cells were switched to Medium A (Dulbecco’s modified Eagle medium containing 10% fetal bovine serum, 100 units/mL penicillin and 100 µg/mL streptomycin sulfate) supplemented with 4 µg/mL puromycin or 10 µg/mL blasticidin for 4 days. Single cell colonies stably expressing POST-3xFlag were obtained by limiting dilution analysis. HeLa/POST1 KO cells and HeLa/S1P KO cells were generated using the CRISPR-Cas9 technology (sgRNAs listed in Supplementary Material, Table S4) and isolated by limiting dilution analysis.

HeLa and HeLa/POST1 KO cells were maintained in Medium A. HeLa/S1P KO cells were maintained in Medium A supplemented with 5 mg/mL cholesterol, 1 mmol/L mevalonate and 20 mmol/L oleic acid. The depletion medium was DMEM supplemented with 5% LPDS, 1 µmol/L lovastatin and 10 µmol/L mevalonate. 1 µg/mL 25-HC or 50 µg/mL LDL was added into the depletion medium if required. Cells were grown in a monolayer at 37 °C with 5% CO2.

Genome-wide CRISPR/Cas9 screen coupled to AmB selection

HeLa/Cas9-Flag cells were transduced with lentivirus expressing a pooled GeCKO v2 library containing 65,383 sgRNAs targeting 19,050 human genes (3 sgRNAs per coding gene and 4 sgRNAs per microRNA) at 0.3 multiplicity of infection. Cells were incubated with Medium A containing 4 µg/mL puromycin for 4 days and then Medium A for another 3 days. A subpopulation of cells was collected to evaluate sgRNA target diversity. A greater than 300x library coverage was achieved. Transduced HeLa/Cas9-Flag cells were treated with the depletion medium for 16 h and then incubated with the depletion medium plus 50 µg/mL LDL and, if necessary, 2 µg/mL U18666A for 4 h. Cells were then incubated in the depletion medium supplemented with 50 µg/mL LDL and 300 µg/mL amphotericin B for 1 h. Cells were washed with PBS and incubated with Medium A for 4 days. A total of 5 rounds of “cholesterol depletion-repletion-AmB selection” was performed. The sgRNA inserts from surviving cells and those from transduced cells prior to the first round of selection were amplified and subjected to deep sequencing.

Immunofluorescence

Cells grown on coverslips were fixed with 4% paraformaldehyde for 30 min and treated with 0.2% Triton X-100 in PBS for 5 min. Cells were washed with PBS and incubated with primary antibodies for 1 h at room temperature. After washing with PBS, cells were incubated with 3% bovine serum albumin (BSA) in PBS and appropriate secondary antibodies at a concentration of 1:1,000 for 1 h at room temperature. Cells were finally counterstained with 300 nmol/L DAPI in PBS for 5 min.

Confocal images were acquired by a Leica Biosystems SP8 laser scanning microscope. The contours of cell, Golgi and nuclei were outlined manually, and background-subtracted fluorescent intensity was quantified using ImageJ.

Lysotracker and filipin staining

Cells were transfected with the indicated siRNA for 48 h and incubated with Medium A supplemented with 100 nmol/L Lysotracker for 30 min. Cells were then fixed and stained with 50 µg/mL filipin (prepared as 5 mg/mL stock solution in ethanol) in PBS for 1 h at room temperature.

Immunoblotting analysis

Cells at a confluency of 80%–90% were harvested and homogenized with 120 µL of RIPA buffer supplemented with protease inhibitors. After centrifuging at 13,400 ×g for 10 min, supernatants were collected and protein concentration was determined using the BCA kit (ThermoFisher Scientific). If needed, 10 units/µL endoglycosidase H or 5 units/µL peptide N-glycosidase F was incubated with supernatants at 37 °C for 1 h. Supernatants were mixed with 4× loading buffer and boiled for 10 min. Proteins were resolved by SDS-PAGE and transferred to PVDF membrane. Blots were blocked with 5% BSA in TBS plus 0.075% Tween (TBST) and probed with primary antibodies overnight at 4 °C. After TBST wash, blots were incubated with secondary antibodies for 1 h at room temperature.

Analysis of SREBP2 cleavage

Cells were transfected with the indicated siRNAs for 48 h and incubated with Medium A, the depletion medium or the depletion medium plus 25-HC for 16 h. For SREBP2 cleavage analysis using whole cell lysates, cells were treated with N-acetyl-leucinal-leucinal-
norleucinal at a final concentration of 25 μg/mL for 1 h at 37 °C prior to harvesting.

For membrane fractionation, cells were incubated with buffer A (10 mmol/L HEPES/KOH, pH 7.6, 1.5 mmol/L MgCl2, 10 mmol/L KCl, 5 mmol/L EDTA, 5 mmol/L EGTA, 250 mmol/L sucrose) containing protease inhibitors on ice for 15 min. Cells were homogenized by passing through a 22G needle 30 times. After centrifuging at 1,000 ×g for 10 min, supernatants and pellets were separately collected. Supernatants were centrifuged at 20,000 ×g for 15 min at 4 °C, and pellet of this centrifugation (designated membrane fraction) was resuspended with SDS lysis buffer (10 mmol/L Tris-HCl, pH 6.8, 100 mmol/L NaCl, 1% (w/v) SDS, 1 mmol/L EDTA, 1 mmol/L EGTA) and mixed with 4× loading buffer. On the other hand, pellets were resuspended with buffer C (20 mmol/L HEPES/KOH, pH 7.6, 2.5% (v/v) glycerol, 1.5 mmol/L MgCl2, 0.42 mol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA) containing protease inhibitors and incubated at 4 °C for 1 h. Nuclear suspension was spun down at 13,200 rpm at 4 °C for 18 min, and supernatant of this centrifugation (designated nuclear extract) was collected and mixed with 4× loading buffer.

**Quantitative real-time PCR**

Total RNA was extracted from HeLa cells transfected with the indicated siRNAs (listed in Supplementary Material, Table S5) or indicated knockout cells using TRIzol (Invitrogen No. 15596018). Equal amounts of RNA were used for cDNA synthesis followed by quantitative real-time PCR as previously described (37). The relative mRNA levels were calculated using the comparative CT method. Human GAPDH was used as the control. All qPCR primers are listed in Supplementary Material, Table S6. Gene expression in cells transfected with scramble siRNAs was defined as 1.

**Mass spectrometry**

HeLa cells or HeLa/POST-3×Flag cells were homogenized in NP40 buffer (0.5% NP40 in PBS containing 5 mmol/L EDTA). After centrifuging at 2,000 ×g for 10 min, supernatants were collected and pre-clear with protein A/G beads at 4 °C for 1 h. Mixtures were centrifuged at 1,000 ×g for 10 min, and supernatants were incubated with anti-Flag beads at 4 °C for 4 h. Beads were spun down and washed with NP40 buffer for 5 times, and proteins coupled to the beads were eluted by 0.1 mg/ml 3×Flag peptides. Eluents were collected and analyzed by liquid chromatograph-mass spectrometer. The intensity of protein present in HeLa/POST-3×Flag cells divided by that in HeLa cells was defined as fold change. Proteins with fold change >1.5 were collected, and those detected in all three independent experiments were identified as POST1-interacting proteins.

**Statistical analysis**

Data were expressed as means ± SD and analyzed by GraphPad Prism 6 software. Sample sizes, biological duplicates, statistical tests, P values were indicated in the figure legends. Statistical significance was set at P < 0.05.

**ACKNOWLEDGMENTS**

We thank Ms. D. Liang and B.-Y. Xiang for technical assistance. This work was supported by grants from the National Natural Science Foundation of China (Grant Nos. 91954203, 31771568, 91754102 and 31690102), Ministry of Science and Technology of China (2016YFA0500100) and 111 Project of Ministry of Education of China (B16036). B.-L. Song acknowledges the support from the Tencent Foundation through the XPLORER PRIZE.

**ABBREVIATIONS**

ACAT2, acetyl-CoA acetyltransferase 2; ACC1, acetyl-coA carboxylase 1; ACLY, ATP (adenosine-triphosphate) citrate lyase; ACSL1, acyl-CoA synthetase long chain family member 1; ALDOB, fructose-bisphosphate aldolase C; AmB, amphotericin B; ACSS2, acyl-CoA synthetase short chain family member 2; AP1M2, adaptor related protein complex 1 subunit mu 2; ATF6, activating transcription factor 6; CREB3, cAMP response element-binding protein 3; BHLHE40, basic helix-loop-helix family member e40; BM, B/B cleavage site mutant; Cas9, CRISPR-associated protein 9; CAVIN3, caveolae associated protein 3; CREB3L3, cAMP responsive element binding protein 3 like 3; CHC, clathrin heavy chain; CM, C/C cleavage site mutant; CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats; CYP51A1, cytochrome P450 family 51 subfamily A member 1; DHCR7, 7-dehydrocholesterol reductase; EGFP, enhanced green fluorescent protein; DHCR24, 24-dehydrocholesterol reductase; EBP, emopamil binding protein; EM, enzymatically inactive mutant; ELOVL6, elongation of very long chain fatty acids protein 6; Endo H, endoglycosidase H; ERG28, ergosterol biosynthesis 28 homolog; ERLINs, ER lipid raft associated proteins; FBS, fetal bovine serum; FADS1, fatty acid desaturase 1; FASN, fatty acid synthase; FDF1, farnesyl-diphosphatase farnsylationtransferase 1; FDPs, farnesyl diphosphate synthase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GeCKO, genome-scale CRISPR/Cas9 knockout; GM130, Golgi matrix protein 130 kD; GNPTAB, N-acetylglucosamine-1-phosphate transferase subunits alpha and beta; HMGCGR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; HMGGCS1, 3-hydroxy-3-methylglutaryl-CoA synthase 1; HSD17B7, hydroxysteroid 17-beta dehydrogenase 7; 25-HC, 25-hydroxycholesterol; ID11, isopentenyl-diphosphatase delta isomerase 1; INSIGs, insulin induced genes; INSIG1, insulin induced gene 1; INSIG2, insulin induced gene 2; LBPA, lyso-bis-phosphatidic acid; LDL, low-density lipoprotein; LDLR, LDL receptor; LBH1D1, LBH domain-containing protein 1; LPIN1, lipin1; LSS, lanosterol synthase; MS/MS, tandem mass spectrometry; MVD, mevalonate diphosphate decarboxylase; M6P, mannose 6-phosphate; NPC1, Niemann-Pick disease type C1; NPR1, natriuretic peptide receptor 1; NSDHL, NAD(P) dependent steroid dehydrogenase-like; n-ATF6, nuclear form of ATF6; n-CREB3L3, nuclear form of CREB3L3; n-SREBP; nuclear form of SREBP; PCK9, proprotein convertase subtilisin/kexin type 9; PCYT2, ethanolamine-phosphate cytidylyltransferase 2; PM, plasma membrane; PNGase F, peptide N-glycosidase F; PNPLA3, patatin like phospholipase domain containing 3; POST1, partner of site-1 protease; SCAP, SREBP-cleavage activating protein; SCD1, stearoyl-CoA desaturase; SC5D, sterol-C5-desaturase; sgRNAs, small guide ribonucleic acid; SLC2A6, solute carrier family 2 member 6; SLC25A1, solute carrier family 25 member 1; SLE, squalene epoxide; SREBF2, sterol regulatory element binding transcription factor 2; SREBFs, sterol-regulatory element binding proteins; STARD4, STAR related lipid transfer domain containing 4; S1P, site-1 protease; ER, endoplasmic...
reticulum; S2P, site-2 protease; TMEM97, transmembrane protein 97; TRC8, translocation in renal cancer from chromosome 8.

**COMPLIANCE WITH ETHICS GUIDELINES**

Jian Xiao, Yanni Xiong, Liu-Ting Yang, Ju-Qiong Wang, Zi-Mu Zhou, Le-Wei Dong, Xiong-Jie Shi, Xiaolu Zhao, Jie Luo and Bao-Liang Song declare that they have no conflict of interests.

This article does not contain any studies with human or animal subjects performed by any of the authors.

**OPEN ACCESS**

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**REFERENCES**

Aregger M, Lawson AK, Billmann M, Costanzo M, Tong AH, Chan K, Rahman M, Brown KR, Ross C, Usaj M et al (2020) Systematic mapping of genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a regulator of lipid metabolism. Nat Metab

Bayraktar EC, La K, Karpman K, Unlu G, Ozerdem C, Ritter DJ, Alwaseem H, Molina H, Hoffmann HH, Millner A et al (2020) Metabolic coessentiality mapping identifies C12orf49 as a regulator of SREBP processing and cholesterol metabolism. Nat Metab

Brown MS, Goldstein JL (1999) A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci USA 96:11041–11048

Brown MS, Radhakrishnan A, Goldstein JL (2018) Retrospective on cholesterol homeostasis: the central role of Scap. Annu Rev Biochem 87:783–807

Burke AC, Dron JS, Hegele RA, Huff MW (2017) PCSK9: regulation and target for drug development for dyslipidemia. Ann Rev Pharmacol Toxicol 57:223–244

Chen L, Chen XW, Huang X, Song BL, Wang Y, Wang Y (2019) Regulation of glucose and lipid metabolism in health and disease. Sci China Life Sci 62:1420–1458

Cheng D, Espenshade PJ, Slaughter CA, Jaen JC, Brown MS, Goldstein JL (1999) Secreted site-1 protease cleaves peptides corresponding to luminal loop of sterol regulatory element-binding proteins. J Biol Chem 274:22805–22812

Chu BB, Liao YC, Qi W, Xie C, Du XM, Wang J, Yang H, Miao HH, Li BL, Song BL (2015) Cholesterol transport through lysosomal-peroxisome membrane contacts. Cell 161:291–306

da Palma JR, Burri DJ, Oppliger J, Salamina M, Cendron L, de Laureto PP, Seidah NG, Kunz S, Pasquato A (2014) Zymogen activation and subcellular activity of subtilisin kexin isozyme 1/site 1 protease. J Biol Chem 289:35743–35756

da Palma JR, Cendron L, Seidah NG, Pasquato A, Kunz S (2016) Mechanism of folding and activation of subtilisin kexin isozyme-1 (SKI-1)/site-1 protease (S1P). J Biol Chem 291:2055–2066

DeBose-Boyd RA, Brown MS, Li WP, Nothurff A, Goldstein JL, Espenshade PJ (1999) Transport-dependent proteolysis of SREBP: relocation of site-1 protease from Golgi to ER obviates the need for SREBP transport to Golgi. Cell 99:703–712

Du XM, Kristiana I, Wong J, Brown AJ (2006) Involvement of Akt in ER-to-Golgi transport of SCAP/SREBP: a link between a key cell proliferative pathway and membrane synthesis. Mol Biol Cell 17:2735–2745

Elagaz O, Benjannet S, Mammarbassi A, Wickham L, Seidah NG (2002) Biosynthesis and cellular trafficking of the convertase SKI-1/S1P: ectodomain shedding requires SKI-1 activity. J Biol Chem 277:11265–11275

Espenshade PJ, Cheng D, Goldstein JL, Brown MS (1999) Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins. J Biol Chem 274:22795–22804

Goldstein JL, Brown MS (2009) The LDL receptor. Arterioscl Throm Vas 29:431–438

Horton JD, Goldstein JL, Brown MS (2002) SREBP: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125–1131

Huber MD, Vesely PW, Datta K, Gerace L (2013) Erlins restrict SREBP activation in the ER and regulate cellular cholesterol homeostasis. J Cell Biol 203:427–436

Ikonen E (2006) Mechanisms for cellular cholesterol transport: defects and human disease. Physiol Rev 86:1237–1261

Infante RE, Radhakrishnan A (2017) Continuous transport of a small fraction of plasma membrane cholesterol to endoplasmic reticulum regulates total cellular cholesterol. eLife 6:e25466

Irisawa M, Inoue J, Ozawa N, Mori K, Sato R (2009) The sterol-sensing endoplasmic reticulum (ER) membrane protein TRC8 hampers ER to Golgi transport of sterol regulatory element-binding protein-2 (SREBP-2)/SREBP cleavage-activated protein and reduces SREBP-2 cleavage. J Biol Chem 284:28995–29004

Kuzu OF, Noory MA, Robertson GP (2016) The role of cholesterol in cancer. Cancer Res 76:2063–2070

Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, Irizarry RA, Liu JS, Brown M, Liu XS (2014) MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol 15:554

Loregger A, Raaben M, Nieuwenhuis J, Tan JME, Jae LT, van den Hengel LG, Hendrix S, van den Berg M, Scheij S, Song JY et al (2020) Haploid genetic screens identify SPRING/C12ORF49 as a determinant of SREBP signaling and cholesterol metabolism. Nat Commun 11:1128

Lu F, Liang Q, Abi-Mosleh L, Das A, De Brabander JK, Goldstein JL, Brown MS (2015) Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection. eLife 4:e12177
Luo J, Jiang L, Yang H, Song BL (2017) Routes and mechanisms of post-endosomal cholesterol trafficking: A story that never ends. Traffic 18:209–217
Luo J, Jiang LY, Yang HY, Song BL (2019) Intracellular cholesterol transport by sterol transfer proteins at membrane contact sites. Trends Biochem Sci 44:273–292
Luo J, Yang H, Song BL (2020) Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol 21:225–245
Marschner K, Kollmann K, Schweizer M, Braulke T, Pohl S (2011) A key enzyme in the biogenesis of lysosomes is a protease that regulates cholesterol metabolism. Science 333:87–90
Radhakrishnan A, Ikeda Y, Kwon HJ, Brown MS, Goldstein JL (2007) Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc Natl Acad Sci USA 104:6511–6518
Sanjana NE, Shalem O, Zhang F (2014) Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 11:783–784
Seidah NG, Prat A (2012) The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11:367–383
Shao W, Espenshade PJ (2014) Sterol regulatory element-binding protein (SREBP) cleavage regulates Golgi-to-endoplasmic reticulum recycling of SREBP cleavage-activating protein (SCAP). J Biol Chem 289:7547–7557
Su L, Zhou LK, Chen FJ, Wang HM, Qian H, Sheng YY, Zhu YG, Yu H, Gong XQ, Cai L et al (2019) Cideb controls sterol-regulated ER export of SREBP/SCAP by promoting cargo loading at ER exit sites. EMBO J 38:e100156
Tiede S, Storch S, Lubke T, Henriessat B, Bargal R, Raas-Rothschild A, Braulke T (2005) Mucolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase. Nat Methods 11:1109–1112
Wei J, Zhang YY, Luo J, Wang JQ, Zhou YX, Miao HH, Shi XJ, Qu YX, Xu J, Li BL, Song BL (2017) The GARP complex is involved in intracellular cholesterol transport via targeting NPC2 to lysosomes. Cell Rep 19:2823–2835
Xiao J, Luo J, Hu A, Xiao T, Li M, Kong Z, Jiang L, Zhou Z, Liao Y, Xie C et al (2019) Cholesterol transport through the peroxisome-ER membrane contacts tethered by P(4,5)P2 and extended synaptotagmins. Sci China Life Sci 62:1117–1135
Xu DQ, Wang Z, Zhang YX, Jiang W, Pan Y, Song BL, Chen Y (2015) PAQR3 modulates cholesterol homeostasis by anchoring Scap/SREBP complex to the Golgi apparatus. Nat Commun 6:8100
Xu M, Liu K, Swaroop M, Sun W, Dehdashti SJ, McKew JC, Zheng W (2014) A phenotypic compound screening assay for lysosomal storage diseases. J Biomol Screen 19:168–175
Ye J, Rawson RB, Komuro R, Chen X, Dave UP, Prywes R, Brown MS, Goldstein JL (2000) ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell 6:1355–1364
Zhang K, Shen X, Wu J, Sakaki K, Saunders T, Rutkowski DT, Back SH, Kaufman RJ (2006) Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell 124:587–599